MELT-300, a non-IV, non-opioid sedation tablet, showed positive Phase 3 results for cataract surgery, supporting FDA ...

Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of MELT-300, a non-intravenous, ...

In the 1990s, overprescribing by doctors, along with aggressive and deceptive drug marketing by pharmaceutical companies, led ...

Objectives Analgesia and sedation are common therapies in pediatric ... discussed iatrogenic withdrawal syndrome following either opioid or benzodiazepine therapy in children in acute or intensive ...

The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...

Melt Pharmaceuticals announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product ...

The trial involved over 530 patients across 13 US clinical sites. Credit: Lucky Business/Shutterstock. Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of ...

Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of MELT-300, a non-intravenous, non-opioid sedation tablet for cataract surgery. The pivotal study's design ...

The opioid crisis remains a significant public health challenge in the United States. In 2022, over 2.5 million American adults had an opioid use disorder, and opioids accounted for nearly 76% of ...